Galectin Cost Of Revenue vs Ebitda Analysis

GALT Stock

USD 1.04 0.96 48.00%

Galectin Therapeutics financial indicator trend analysis is much more than just examining Galectin Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Galectin Therapeutics is a good investment. Please check the relationship between Galectin Therapeutics Cost Of Revenue and its Ebitda accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Cost Of Revenue vs Ebitda

Cost Of Revenue vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Galectin Therapeutics Cost Of Revenue account and Ebitda. At this time, the significance of the direction appears to have weak relationship.

The correlation between Galectin Therapeutics' Cost Of Revenue and Ebitda is 0.38. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Ebitda in the same time period over historical financial statements of Galectin Therapeutics, assuming nothing else is changed. The correlation between historical values of Galectin Therapeutics' Cost Of Revenue and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Galectin Therapeutics are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Cost Of Revenue i.e., Galectin Therapeutics' Cost Of Revenue and Ebitda go up and down completely randomly.

Correlation Coefficient

0.38

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Galectin Therapeutics income statement and represents the costs associated with goods and services Galectin Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Ebitda

Most indicators from Galectin Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Galectin Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.Enterprise Value is likely to gain to about 104.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 5.3 M in 2024.

Galectin Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant And Equipment Net	Other Assets	Other Current Assets	Property Plant And Equipment Gross	Property Plant Equipment	Current Deferred Revenue	Non Current Liabilities Total
Total Assets		0.18	0.26	0.26	0.25	-0.32	-0.5	0.25	1.0	0.05	0.07	1.0	0.68	0.59	0.63	0.2	1.0	-0.51	0.68	0.04	0.2	0.53	0.1	-0.03	-0.46	0.14
Short Long Term Debt Total	0.18		0.92	0.97	-0.89	0.87	-0.79	0.97	0.14	0.72	0.67	0.15	0.49	0.67	0.67	1.0	0.17	-0.08	0.51	0.0	0.19	0.42	0.07	-0.28	-0.27	0.99
Other Current Liab	0.26	0.92		0.98	-0.8	0.77	-0.89	0.89	0.21	0.74	0.72	0.21	0.66	0.81	0.79	0.93	0.25	-0.28	0.69	0.18	0.47	0.64	0.26	-0.35	-0.35	0.89
Total Current Liabilities	0.26	0.97	0.98		-0.84	0.8	-0.88	0.96	0.22	0.77	0.75	0.22	0.63	0.8	0.78	0.97	0.25	-0.18	0.65	0.13	0.33	0.56	0.21	-0.32	-0.35	0.94
Total Stockholder Equity	0.25	-0.89	-0.8	-0.84		-0.99	0.55	-0.83	0.28	-0.7	-0.65	0.28	-0.21	-0.39	-0.36	-0.89	0.26	-0.11	-0.22	-0.02	-0.18	-0.17	-0.05	0.31	0.03	-0.91
Net Debt	-0.32	0.87	0.77	0.8	-0.99		-0.52	0.8	-0.36	0.68	0.63	-0.35	0.17	0.36	0.33	0.86	-0.33	0.18	0.18	0.01	0.13	0.16	0.04	-0.26	-0.03	0.88
Retained Earnings	-0.5	-0.79	-0.89	-0.88	0.55	-0.52		-0.83	-0.46	-0.73	-0.73	-0.46	-0.87	-0.97	-0.97	-0.8	-0.49	0.39	-0.89	-0.27	-0.4	-0.67	-0.38	0.24	0.6	-0.73
Accounts Payable	0.25	0.97	0.89	0.96	-0.83	0.8	-0.83		0.22	0.77	0.73	0.22	0.54	0.72	0.73	0.97	0.24	-0.04	0.56	0.05	0.09	0.41	0.12	-0.26	-0.34	0.95
Cash	1.0	0.14	0.21	0.22	0.28	-0.36	-0.46	0.22		0.01	0.03	1.0	0.64	0.55	0.6	0.16	1.0	-0.51	0.64	0.02	0.16	0.49	0.08	-0.02	-0.44	0.11
Non Current Assets Total	0.05	0.72	0.74	0.77	-0.7	0.68	-0.73	0.77	0.01		1.0	0.01	0.55	0.66	0.63	0.72	0.03	0.06	0.57	0.51	0.35	0.23	0.57	-0.12	-0.25	0.69
Non Currrent Assets Other	0.07	0.67	0.72	0.75	-0.65	0.63	-0.73	0.73	0.03	1.0		0.03	0.58	0.68	0.65	0.68	0.06	0.04	0.6	0.57	0.4	0.25	0.63	-0.09	-0.26	0.65
Cash And Short Term Investments	1.0	0.15	0.21	0.22	0.28	-0.35	-0.46	0.22	1.0	0.01	0.03		0.64	0.56	0.6	0.17	1.0	-0.51	0.64	0.02	0.16	0.49	0.08	-0.02	-0.44	0.12
Common Stock Total Equity	0.68	0.49	0.66	0.63	-0.21	0.17	-0.87	0.54	0.64	0.55	0.58	0.64		0.92	0.91	0.5	0.67	-0.39	1.0	0.34	0.47	0.71	0.46	0.02	-0.55	0.42
Common Stock Shares Outstanding	0.59	0.67	0.81	0.8	-0.39	0.36	-0.97	0.72	0.55	0.66	0.68	0.56	0.92		0.99	0.69	0.59	-0.42	0.94	0.27	0.45	0.76	0.4	-0.1	-0.59	0.61
Other Stockholder Equity	0.63	0.67	0.79	0.78	-0.36	0.33	-0.97	0.73	0.6	0.63	0.65	0.6	0.91	0.99		0.68	0.62	-0.46	0.93	0.27	0.38	0.71	0.4	-0.17	-0.65	0.6
Total Liab	0.2	1.0	0.93	0.97	-0.89	0.86	-0.8	0.97	0.16	0.72	0.68	0.17	0.5	0.69	0.68		0.19	-0.11	0.52	0.01	0.23	0.45	0.07	-0.31	-0.25	0.99
Total Current Assets	1.0	0.17	0.25	0.25	0.26	-0.33	-0.49	0.24	1.0	0.03	0.06	1.0	0.67	0.59	0.62	0.19		-0.51	0.67	0.03	0.19	0.53	0.09	-0.03	-0.45	0.14
Short Term Debt	-0.51	-0.08	-0.28	-0.18	-0.11	0.18	0.39	-0.04	-0.51	0.06	0.04	-0.51	-0.39	-0.42	-0.46	-0.11	-0.51		-0.42	0.04	-0.49	-0.41	-0.02	0.55	0.47	-0.06
Common Stock	0.68	0.51	0.69	0.65	-0.22	0.18	-0.89	0.56	0.64	0.57	0.6	0.64	1.0	0.94	0.93	0.52	0.67	-0.42		0.36	0.51	0.74	0.48	0.01	-0.56	0.44
Property Plant And Equipment Net	0.04	0.0	0.18	0.13	-0.02	0.01	-0.27	0.05	0.02	0.51	0.57	0.02	0.34	0.27	0.27	0.01	0.03	0.04	0.36		0.45	-0.02	0.97	-0.02	-0.22	-0.04
Other Assets	0.2	0.19	0.47	0.33	-0.18	0.13	-0.4	0.09	0.16	0.35	0.4	0.16	0.47	0.45	0.38	0.23	0.19	-0.49	0.51	0.45		0.52	0.51	-0.15	-0.14	0.19
Other Current Assets	0.53	0.42	0.64	0.56	-0.17	0.16	-0.67	0.41	0.49	0.23	0.25	0.49	0.71	0.76	0.71	0.45	0.53	-0.41	0.74	-0.02	0.52		0.09	-0.08	-0.34	0.36
Property Plant And Equipment Gross	0.1	0.07	0.26	0.21	-0.05	0.04	-0.38	0.12	0.08	0.57	0.63	0.08	0.46	0.4	0.4	0.07	0.09	-0.02	0.48	0.97	0.51	0.09		0.08	-0.27	0.02
Property Plant Equipment	-0.03	-0.28	-0.35	-0.32	0.31	-0.26	0.24	-0.26	-0.02	-0.12	-0.09	-0.02	0.02	-0.1	-0.17	-0.31	-0.03	0.55	0.01	-0.02	-0.15	-0.08	0.08		0.32	-0.29
Current Deferred Revenue	-0.46	-0.27	-0.35	-0.35	0.03	-0.03	0.6	-0.34	-0.44	-0.25	-0.26	-0.44	-0.55	-0.59	-0.65	-0.25	-0.45	0.47	-0.56	-0.22	-0.14	-0.34	-0.27	0.32		-0.2
Non Current Liabilities Total	0.14	0.99	0.89	0.94	-0.91	0.88	-0.73	0.95	0.11	0.69	0.65	0.12	0.42	0.61	0.6	0.99	0.14	-0.06	0.44	-0.04	0.19	0.36	0.02	-0.29	-0.2

Click cells to compare fundamentals

Galectin Therapeutics Account Relationship Matchups

Galectin Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	48.5M	29.6M	41.8M	21.3M	28.2M	14.9M
Other Current Liab	1.1M	4.1M	7.2M	9.1M	9.2M	9.7M
Total Current Liabilities	2.8M	5.4M	9.0M	13.0M	15.7M	16.5M
Total Stockholder Equity	45.6M	29.6M	893K	(33.9M)	(60.2M)	(57.2M)
Net Debt	(47.4M)	(27.1M)	(10.6M)	21.3M	46.1M	48.5M
Retained Earnings	(216.4M)	(240.0M)	(270.7M)	(309.6M)	(354.4M)	(336.7M)
Accounts Payable	1.7M	1.3M	1.8M	3.9M	6.4M	6.8M
Cash	47.5M	27.1M	39.6M	18.6M	25.7M	13.8M
Non Current Assets Total	258K	135K	7K	733K	490K	514.5K
Non Currrent Assets Other	258K	135K	7K	733K	437K	458.9K
Cash And Short Term Investments	47.5M	27.1M	39.6M	18.6M	25.7M	14.0M
Common Stock Shares Outstanding	52.2M	57.0M	58.5M	59.4M	60.2M	63.2M
Liabilities And Stockholders Equity	48.5M	29.6M	41.8M	21.3M	28.2M	14.9M
Other Stockholder Equity	259.7M	261.9M	271.0M	275.1M	293.6M	308.2M
Total Liab	2.9M	5.4M	40.9M	55.2M	88.4M	92.9M
Total Current Assets	48.2M	29.5M	41.8M	20.6M	27.7M	14.7M
Common Stock	36K	41K	56K	59K	61K	39.3K
Property Plant And Equipment Net	258K	135K	7K	733K	53K	50.4K
Other Current Assets	729K	4.6M	4.3M	2.0M	2.1M	2.2M
Non Current Liabilities Total	52K	(5.4M)	31.9M	42.2M	72.8M	76.4M
Retained Earnings Total Equity	(181.2M)	(196.2M)	(216.4M)	(240.0M)	(216.0M)	(226.8M)
Net Tangible Assets	45.1M	21.9M	366K	(34.4M)	(31.0M)	(29.4M)
Capital Surpluse	173.4M	194.1M	259.7M	261.9M	301.2M	200.2M
Net Invested Capital	43.3M	21.9M	29.4M	5.4M	9.3M	15.6M
Net Working Capital	45.4M	24.1M	32.8M	7.5M	12.0M	20.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC